After a six-month treatment period, no significant improvements were noted in cognitive function, global clinical impression, or neuropsychiatric symptoms among AD patients who were also taking stable doses of cholinesterase inhibitors as combination therapy [199]. The gene discussed is BCHE; the disease is Alzheimer disease.